Key data
Open—
From 52W high—
Volume—
Market cap—
P/E (TTM)—
P/S (TTM)—
Div yield—
Key data
Open
—
From 52W high
—
Volume
—
Market cap
—
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
—
P/E (TTM)
—
RSI (14)
—
MomentumView details →
1D Return
—
YTD Return
—
SummaryUpdated Jun 1, 2026
Evotec SE (NASDAQ:EVO) is a German drug discovery and development company founded in 1993 and headquartered in Hamburg. Originally incorporated as Evotec AG, the company changed its name to Evotec SE in April 2019 and went public in 2004. Evotec operates as a strategic partner to pharmaceutical and biotechnology companies worldwide, providing integrated drug discovery services and biologics manufacturing capabilities. The company has evolved from a traditional contract research organization into a technology-driven platform that combines advanced scientific capabilities with manufacturing expertise to accelerate drug development across multiple therapeutic areas.
Latest newsMore news →
Evotec SE initiated a Phase 1 clinical trial for JST-018, a cocktail of investigational monoclonal antibodies targeting orthopoxviruses, developed by its subsidiary Just - Evotec Biologics under the U.S. Department of War's Accelerated Antibodies Program.11d agoEvotec SE and Plectonic Biotech announced a research collaboration to explore a novel immunotherapy approach for solid tumors, combining Evotec's BiTco costimulatory CD2 bispecifics platform with Plectonic's LOGIBODY® technology.18d ago